抗CD20（利妥昔单抗）在严重的、危及生命的儿童免疫性血小板减少性紫癜中的成功应用。
Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
作者信息
Bengtson Kristi L, Skinner Michael A, Ware Russell E
机构信息
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA.
出版信息
J Pediatr. 2003 Nov;143(5):670-3. doi: 10.1067/S0022-3476(03)00446-3.
Abstract
Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.
摘要
儿童免疫性血小板减少性紫癜伴危及生命的出血较为罕见，但对于出血患者，有效的治疗选择有限。我们报告了人源化抗CD20单克隆抗体（利妥昔单抗，美罗华）治疗一名患有严重、难治性、危及生命的免疫性血小板减少性紫癜婴儿的疗效。
Zotero 插件